Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach
The PopPK and PopPD models well described the PK and PD profiles of nemolizumab in patients with PN. MBMA demonstrated that nemolizumab was superior to dupilumab in improving response rates in patients with PN. These findings, derived from pharmacometrics modeling and indirect comparison, may help inform future clinical studies and support the ongoing evaluation of nemolizumab in PN.
Authors
- Kenji Kabashima (ORCID: https://orcid.org/0000-0002-0773-0554)
- Tomoki Takechi (ORCID: https://orcid.org/0000-0003-1628-4979)
- Ichiro Ieiri
- Junya Shimizu (ORCID: https://orcid.org/0000-0002-2298-4632)
Institutions
- Agency for Science, Technology and Research (SG)
- Kyoto University (JP)
- Singapore Immunology Network (SG)
- Fukuoka International University (JP)
- Kyoto Research Park (JP)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s13555-025-01554-4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical